Menu
1 min read · estimated
APPROVED USE
What FDA approved
Traditional approval of the 400 mg every-six-weeks IV dosing option for eligible adults with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma under the existing indications.
LAMPGEN ANALYSIS
Why it matters
The conversion resolves the earlier accelerated approval for the less frequent lymphoma dosing schedule.
What research teams should watch
Keep lymphoma dosing pathways distinct from pediatric schedules and document the intended regimen and visit interval.
PRIMARY RECORDS